FDA Advisory Committee stalemates on delavirdine.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D002986:Clinical Trials as Topic; D020008:Delavirdine; D018450:Disease Progression; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004347:Drug Interactions; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D010879:Piperazines / Q000008:administration & dosage*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load
D007211:Indoles; D010879:Piperazines; D018894:Reverse Transcriptase Inhibitors; D020008:Delavirdine